View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPharmaLundensis 将来の成長Future 基準チェック /06現在、 PharmaLundensisの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長31.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 22PharmaLundensis AB to Report Q1, 2026 Results on May 21, 2026PharmaLundensis AB announced that they will report Q1, 2026 results on May 21, 2026お知らせ • Jan 23PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million. Security Name: Shares Security Type: Common Stock Securities Offered: 39,994,512 Price\Range: SEK 0.5 Transaction Features: Rights Offeringお知らせ • Jan 21PharmaLundensis AB to Report Fiscal Year 2025 Results on Feb 19, 2026PharmaLundensis AB announced that they will report fiscal year 2025 results on Feb 19, 2026お知らせ • Oct 22PharmaLundensis AB to Report Q3, 2025 Results on Nov 20, 2025PharmaLundensis AB announced that they will report Q3, 2025 results on Nov 20, 2025お知らせ • Jul 23PharmaLundensis AB to Report Q2, 2025 Results on Aug 21, 2025PharmaLundensis AB announced that they will report Q2, 2025 results on Aug 21, 2025お知らせ • Jun 10PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million. Security Name: Shares Security Type: Common Stock Securities Offered: 40,184,959 Price\Range: SEK 0.5 Transaction Features: Rights Offeringお知らせ • Apr 02PharmaLundensis AB to Report Q1, 2025 Results on May 01, 2025PharmaLundensis AB announced that they will report Q1, 2025 results on May 01, 2025お知らせ • Feb 06PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 14.439654 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 14.439654 million. Security Name: Shares Security Type: Common Stock Securities Offered: 14,439,654 Price\Range: SEK 1 Transaction Features: Rights Offeringお知らせ • Jan 22PharmaLundensis AB to Report Fiscal Year 2024 Results on Feb 20, 2025PharmaLundensis AB announced that they will report fiscal year 2024 results on Feb 20, 2025お知らせ • Oct 23PharmaLundensis AB to Report Nine Months, 2024 Results on Nov 21, 2024PharmaLundensis AB announced that they will report nine months, 2024 results on Nov 21, 2024お知らせ • Jul 17PharmaLundensis AB to Report Q2, 2024 Results on Aug 15, 2024PharmaLundensis AB announced that they will report Q2, 2024 results on Aug 15, 2024お知らせ • Apr 17PharmaLundensis AB to Report Q1, 2024 Results on May 16, 2024PharmaLundensis AB announced that they will report Q1, 2024 results on May 16, 2024お知らせ • Jan 17PharmaLundensis AB to Report Fiscal Year 2023 Results on Feb 15, 2024PharmaLundensis AB announced that they will report fiscal year 2023 results on Feb 15, 2024お知らせ • Sep 22PharmaLundensis AB to Report Nine Months, 2023 Results on Oct 20, 2023PharmaLundensis AB announced that they will report nine months, 2023 results on Oct 20, 2023Recent Insider Transactions • Sep 07Founder recently bought kr135k worth of stockOn the 5th of September, Staffan Skogvall bought around 225k shares on-market at roughly kr0.60 per share. This transaction amounted to 1.1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr471k worth in shares.お知らせ • Jul 21PharmaLundensis AB to Report Q2, 2023 Results on Aug 17, 2023PharmaLundensis AB announced that they will report Q2, 2023 results on Aug 17, 2023Recent Insider Transactions • Jul 04Founder recently bought kr85k worth of stockOn the 30th of June, Staffan Skogvall bought around 274k shares on-market at roughly kr0.31 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr330k worth in shares.New Risk • Jun 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 22% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr2.3m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr19.5m market cap, or US$1.83m). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding).Recent Insider Transactions • Mar 16Founder recently bought kr96k worth of stockOn the 13th of March, Staffan Skogvall bought around 188k shares on-market at roughly kr0.51 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr283k worth in shares.お知らせ • Jan 18PharmaLundensis AB to Report Fiscal Year 2022 Results on Feb 16, 2023PharmaLundensis AB announced that they will report fiscal year 2022 results on Feb 16, 2023Board Change • Nov 16No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Founder, CEO & Director Staffan Skogvall is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.お知らせ • Oct 19PharmaLundensis AB to Report Q3, 2022 Results on Nov 17, 2022PharmaLundensis AB announced that they will report Q3, 2022 results on Nov 17, 2022Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Founder, CEO & Director Staffan Skogvall is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.お知らせ • Apr 20PharmaLundensis AB to Report Q1, 2022 Results on May 19, 2022PharmaLundensis AB announced that they will report Q1, 2022 results on May 19, 2022Is New 90 Day High Low • Jan 29New 90-day low: kr0.86The company is down 17% from its price of kr1.04 on 29 October 2020. The Swedish market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.Is New 90 Day High Low • Dec 01New 90-day low: kr0.94The company is down 19% from its price of kr1.16 on 01 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.Is New 90 Day High Low • Oct 24New 90-day low: kr1.01The company is down 8.0% from its price of kr1.10 on 23 July 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.Is New 90 Day High Low • Sep 23New 90-day low: kr1.02The company is down 15% from its price of kr1.20 on 25 June 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 16% over the same period.お知らせ • Jul 26PharmaLundensis AB to Report Q2, 2020 Results on Aug 20, 2020PharmaLundensis AB announced that they will report Q2, 2020 results on Aug 20, 2020 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、PharmaLundensis は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NGM:PHAL - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2023N/A-4-4-3N/A9/30/2023N/A-4N/AN/AN/A6/30/2023N/A-3N/AN/AN/A3/31/2023N/A-3N/AN/AN/A12/31/2022N/A-3N/AN/AN/A9/30/2022N/A-3N/AN/AN/A6/30/2022N/A-3N/AN/AN/A3/31/2022N/A-3N/AN/AN/A12/31/2021N/A-3N/AN/AN/A9/30/2021N/A-3N/AN/AN/A6/30/2021N/A-3N/AN/AN/A3/31/2021N/A-3N/AN/AN/A12/31/2020N/A-3N/AN/AN/A9/30/2020N/A-4N/AN/AN/A6/30/2020N/A-4N/AN/AN/A3/31/2020N/A-5N/AN/AN/A12/31/2019N/A-6N/AN/AN/A9/30/2019N/A-6N/AN/AN/A6/30/2019N/A-6N/AN/AN/A3/31/2019N/A-6N/AN/AN/A12/31/2018N/A-5N/AN/AN/A9/30/2018N/A-12N/AN/AN/A6/30/2018N/A-12N/AN/AN/A3/31/2018N/A-12N/AN/AN/A12/31/2017N/A-12N/AN/AN/A9/30/2017N/A-5N/AN/AN/A6/30/2017N/A-5N/AN/AN/A3/31/2017N/A-5N/AN/AN/A12/31/2016N/A-4N/AN/AN/A9/30/2016N/A-4N/AN/AN/A6/30/2016N/A-4N/AN/AN/A3/31/2016N/A-4N/AN/AN/A12/31/2015N/A-4N/AN/AN/A9/30/2015N/A-4N/AN/AN/A6/30/2015N/A-4N/AN/AN/A3/31/2015N/A-5N/AN/AN/A12/31/2014N/A-6N/AN/AN/A9/30/2014N/A-6N/AN/AN/A6/30/2014N/A-6N/AN/AN/A3/31/2014N/A-6N/AN/AN/A12/31/20130-7N/AN/AN/A9/30/20130-6N/AN/AN/A6/30/20130-7N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PHALの予測収益成長が 貯蓄率 ( 0.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: PHALの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: PHALの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: PHALの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: PHALの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PHALの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/04/29 11:46終値2024/01/31 00:00収益2023/12/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PharmaLundensis AB 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 22PharmaLundensis AB to Report Q1, 2026 Results on May 21, 2026PharmaLundensis AB announced that they will report Q1, 2026 results on May 21, 2026
お知らせ • Jan 23PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million. Security Name: Shares Security Type: Common Stock Securities Offered: 39,994,512 Price\Range: SEK 0.5 Transaction Features: Rights Offering
お知らせ • Jan 21PharmaLundensis AB to Report Fiscal Year 2025 Results on Feb 19, 2026PharmaLundensis AB announced that they will report fiscal year 2025 results on Feb 19, 2026
お知らせ • Oct 22PharmaLundensis AB to Report Q3, 2025 Results on Nov 20, 2025PharmaLundensis AB announced that they will report Q3, 2025 results on Nov 20, 2025
お知らせ • Jul 23PharmaLundensis AB to Report Q2, 2025 Results on Aug 21, 2025PharmaLundensis AB announced that they will report Q2, 2025 results on Aug 21, 2025
お知らせ • Jun 10PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million. Security Name: Shares Security Type: Common Stock Securities Offered: 40,184,959 Price\Range: SEK 0.5 Transaction Features: Rights Offering
お知らせ • Apr 02PharmaLundensis AB to Report Q1, 2025 Results on May 01, 2025PharmaLundensis AB announced that they will report Q1, 2025 results on May 01, 2025
お知らせ • Feb 06PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 14.439654 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 14.439654 million. Security Name: Shares Security Type: Common Stock Securities Offered: 14,439,654 Price\Range: SEK 1 Transaction Features: Rights Offering
お知らせ • Jan 22PharmaLundensis AB to Report Fiscal Year 2024 Results on Feb 20, 2025PharmaLundensis AB announced that they will report fiscal year 2024 results on Feb 20, 2025
お知らせ • Oct 23PharmaLundensis AB to Report Nine Months, 2024 Results on Nov 21, 2024PharmaLundensis AB announced that they will report nine months, 2024 results on Nov 21, 2024
お知らせ • Jul 17PharmaLundensis AB to Report Q2, 2024 Results on Aug 15, 2024PharmaLundensis AB announced that they will report Q2, 2024 results on Aug 15, 2024
お知らせ • Apr 17PharmaLundensis AB to Report Q1, 2024 Results on May 16, 2024PharmaLundensis AB announced that they will report Q1, 2024 results on May 16, 2024
お知らせ • Jan 17PharmaLundensis AB to Report Fiscal Year 2023 Results on Feb 15, 2024PharmaLundensis AB announced that they will report fiscal year 2023 results on Feb 15, 2024
お知らせ • Sep 22PharmaLundensis AB to Report Nine Months, 2023 Results on Oct 20, 2023PharmaLundensis AB announced that they will report nine months, 2023 results on Oct 20, 2023
Recent Insider Transactions • Sep 07Founder recently bought kr135k worth of stockOn the 5th of September, Staffan Skogvall bought around 225k shares on-market at roughly kr0.60 per share. This transaction amounted to 1.1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr471k worth in shares.
お知らせ • Jul 21PharmaLundensis AB to Report Q2, 2023 Results on Aug 17, 2023PharmaLundensis AB announced that they will report Q2, 2023 results on Aug 17, 2023
Recent Insider Transactions • Jul 04Founder recently bought kr85k worth of stockOn the 30th of June, Staffan Skogvall bought around 274k shares on-market at roughly kr0.31 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr330k worth in shares.
New Risk • Jun 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 22% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr2.3m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr19.5m market cap, or US$1.83m). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding).
Recent Insider Transactions • Mar 16Founder recently bought kr96k worth of stockOn the 13th of March, Staffan Skogvall bought around 188k shares on-market at roughly kr0.51 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr283k worth in shares.
お知らせ • Jan 18PharmaLundensis AB to Report Fiscal Year 2022 Results on Feb 16, 2023PharmaLundensis AB announced that they will report fiscal year 2022 results on Feb 16, 2023
Board Change • Nov 16No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Founder, CEO & Director Staffan Skogvall is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
お知らせ • Oct 19PharmaLundensis AB to Report Q3, 2022 Results on Nov 17, 2022PharmaLundensis AB announced that they will report Q3, 2022 results on Nov 17, 2022
Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Founder, CEO & Director Staffan Skogvall is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
お知らせ • Apr 20PharmaLundensis AB to Report Q1, 2022 Results on May 19, 2022PharmaLundensis AB announced that they will report Q1, 2022 results on May 19, 2022
Is New 90 Day High Low • Jan 29New 90-day low: kr0.86The company is down 17% from its price of kr1.04 on 29 October 2020. The Swedish market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Dec 01New 90-day low: kr0.94The company is down 19% from its price of kr1.16 on 01 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.
Is New 90 Day High Low • Oct 24New 90-day low: kr1.01The company is down 8.0% from its price of kr1.10 on 23 July 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Sep 23New 90-day low: kr1.02The company is down 15% from its price of kr1.20 on 25 June 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 16% over the same period.
お知らせ • Jul 26PharmaLundensis AB to Report Q2, 2020 Results on Aug 20, 2020PharmaLundensis AB announced that they will report Q2, 2020 results on Aug 20, 2020